MENU
GALT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

GALT stock forecast, quote, news & analysis

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
GALT
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GALT with price predictions
Sep 11, 2026

GALT in -5.80% downward trend, sliding for three consecutive days on September 10, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GALT declined for three days, in 242 of 277 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GALT moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GALT as a result. In 90 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for GALT turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 44 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

GALT broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

GALT moved above its 50-day moving average on August 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GALT crossed bullishly above the 50-day moving average on August 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

The 50-day moving average for GALT moved above the 200-day moving average on August 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +13.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in 186 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 188 of 205 cases where GALT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. GALT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 130.64B. VRTX holds the highest valuation in this group at 130.64B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 2,532%. INDP experienced the highest price growth at 127%, while GOSS experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
GALT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of drugs to combat various diseases

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
4960 Peachtree Industrial Boulevard
Phone
+1 678 620-3186
Employees
9
Web
https://www.galectintherapeutics.com
GALT in -5.80% downward trend, sliding for three consecutive days on September 10, 2026